Paper · 36966334
References196
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
1 to 20 of 196
Download this page as JSON| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 23,151,605 | Immunogenic cell death and DAMPs in cancer therapy. | Nat Rev Cancer | 2012 | https://conductscience.org/library/papers/23151605 | PubMed |
| 2 | 36,190,545 | FGFR mRNA Expression in Cholangiocarcinoma and Its Correlation with FGFR2 Fusion Status and Immune Signatures. | Clin Cancer Res | 2022 | https://conductscience.org/library/papers/36190545 | PubMed |
| 3 | 29,508,855 | Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges. | Nat Rev Clin Oncol | 2018 | https://conductscience.org/library/papers/29508855 | PubMed |
| 4 | 10,341,222 | Keratinocyte growth factor induces angiogenesis and protects endothelial barrier function. | J Cell Sci | 1999 | https://conductscience.org/library/papers/10341222 | PubMed |
| 5 | 11,031,111 | Characterization of a novel protein (FGFRL1) from human cartilage related to FGF receptors. | Genomics | 2000 | https://conductscience.org/library/papers/11031111 | PubMed |
| 6 | 29,443,960 | TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. | Nature | 2018 | https://conductscience.org/library/papers/29443960 | PubMed |
| 7 | 33,262,763 | A Window of Opportunity: Targeting Cancer Endothelium to Enhance Immunotherapy. | Front Immunol | 2020 | https://conductscience.org/library/papers/33262763 | PubMed |
| 8 | 30,811,474 | Lenvatinib plus anti-PD-1 antibody combination treatment activates CD8+ T cells through reduction of tumor-associated macrophage and activation of the interferon pathway. | PLoS One | 2019 | https://conductscience.org/library/papers/30811474 | PubMed |
| 9 | 28,187,290 | Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy. | Cell | 2017 | https://conductscience.org/library/papers/28187290 | PubMed |
| 10 | 26,903,404 | Regulation of FGF signaling: Recent insights from studying positive and negative modulators. | Semin Cell Dev Biol | 2016 | https://conductscience.org/library/papers/26903404 | PubMed |
| 11 | 34,343,496 | CXCR6 positions cytotoxic T cells to receive critical survival signals in the tumor microenvironment. | Cell | 2021 | https://conductscience.org/library/papers/34343496 | PubMed |
| 12 | 36,186,672 | Immunotherapy With Checkpoint Inhibitors in FGFR-Altered Urothelial Carcinoma. | Clin Med Insights Oncol | 2022 | https://conductscience.org/library/papers/36186672 | PubMed |
| 13 | 21,436,444 | Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. | Science | 2011 | https://conductscience.org/library/papers/21436444 | PubMed |
| 14 | 10,809,673 | CIITA is a transcriptional coactivator that is recruited to MHC class II promoters by multiple synergistic interactions with an enhanceosome complex. | Genes Dev | 2000 | https://conductscience.org/library/papers/10809673 | PubMed |
| 15 | 26,168,215 | Myeloid-derived suppressor cells in the tumor microenvironment: expect the unexpected. | J Clin Invest | 2015 | https://conductscience.org/library/papers/26168215 | PubMed |
| 16 | 11,282,421 | FGF and VEGF function in angiogenesis: signalling pathways, biological responses and therapeutic inhibition. | Trends Pharmacol Sci | 2001 | https://conductscience.org/library/papers/11282421 | PubMed |
| 17 | 22,422,195 | High expression of CX3CL1 by tumor cells correlates with a good prognosis and increased tumor-infiltrating CD8+ T cells, natural killer cells, and dendritic cells in breast carcinoma. | J Surg Oncol | 2012 | https://conductscience.org/library/papers/22422195 | PubMed |
| 18 | 26,851,185 | Epithelial-Mesenchymal Transition Is Associated with a Distinct Tumor Microenvironment Including Elevation of Inflammatory Signals and Multiple Immune Checkpoints in Lung Adenocarcinoma. | Clin Cancer Res | 2016 | https://conductscience.org/library/papers/26851185 | PubMed |
| 19 | 20,940,169 | Fibroblast growth factors: from molecular evolution to roles in development, metabolism and disease. | J Biochem | 2011 | https://conductscience.org/library/papers/20940169 | PubMed |
| 20 | 29,634,943 | T Cell Dysfunction in Cancer. | Cancer Cell | 2018 | https://conductscience.org/library/papers/29634943 | PubMed |
papers-2026-11-12-0.1.0
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/papers/v1/36966334/references